Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability
FDA has released draft guidance on pharmacokinetics in patients with impaired hepatic function, focusing on study design and dosage impact.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Health systems, medical device companies, health tech startups, and digital health compliance teams. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline mentioned for compliance with the draft guidance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New draft guidance on how to conduct studies and analyze data for pharmacokinetics in patients with liver impairment, affecting dosage recommendations.
Who it affects
Health systems, medical device companies, health tech startups, and digital health compliance teams.
What you must do
Review the draft guidance and adjust study designs and data analysis protocols accordingly.
Deadline
No specific deadline mentioned for compliance with the draft guidance.
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- Louisiana AI Legislative Update - pelicanpolicy.org
- New law aims to curb medical debt, increase transparency in hospital billing - indianapolisrecorder.com
- Illinois’ new AI therapy ban has a loophole - KevinMD.com
- New bill aims to safeguard health care licensing in Delaware - delawareonline.com
- FDA Grants Premarket Approval to AI-Enabled System for Breast Cancer Margin Assessment - targetedonc.com